- Home
- ZNTL vs PROK Comparison
ZNTL vs PROK Comparison
Compare ZNTL & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNTL | PROK |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | 231 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.9M | 359.1M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | PROK |
|---|---|---|
| Price | $4.06 | $1.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $6.60 | ★ $7.40 |
| AVG Volume (30 Days) | ★ 1.0M | 720.8K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $1.13 | $0.54 |
| 52 Week High | $6.95 | $7.13 |
Technical Indicators
Market Signals| Indicator | ZNTL | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 51.88 | 45.39 |
| Support Level | $3.75 | $1.73 |
| Resistance Level | $4.40 | $2.58 |
| Average True Range (ATR) | 0.32 | 0.12 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 59.20 | 46.74 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.